The estimated Net Worth of Igor Matushansky is at least $1.67 Milion dollars as of 21 December 2021. Igor Matushansky owns over 22,853 units of Hookipa Pharma Inc stock worth over $462,063 and over the last 6 years he sold HOOK stock worth over $70,015. In addition, he makes $1,142,710 as Chief Medical Officer and Global Head of Research and Development at Hookipa Pharma Inc.
Sign up
Igor Matushansky HOOK stock SEC Form 4 insiders trading
Igor has made over 5 trades of the Hookipa Pharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 22,853 units of HOOK stock worth $2,285 on 21 December 2021.
The largest trade he's ever made was exercising 49,628 units of Hookipa Pharma Inc stock on 16 December 2020 worth over $4,963. On average, Igor trades about 10,849 units every 61 days since 2019. As of 21 December 2021 he still owns at least 87,512 units of Hookipa Pharma Inc stock.
You can see the complete history of Igor Matushansky stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Igor Matushansky biography
Dr. Igor Matushansky serves as Chief Medical Officer and Global Head of Research and Development of the Company. Dr. Matushansky served as the Global Head of Translational Development for Oncology at Daiichi Sankyo from 2015 to 2017, where he led Daiichi Sankyo's international research unit that focused on early oncology therapeutic programs, strategy and development and was also responsible for a range of development activities, including post-target identification, clinical trials and proof-of-concept research. Before this, Dr. Matushansky worked at Novartis from 2012 to 2015 as both Global Head for Clinical and Scientific Development in the Gene & Cell Therapy Unit and as Global Clinical Program Lead within the Oncology Translational Medicine Unit. Prior to this, he was a Professor at Columbia University Medical Center from 2007 to 2012 where he ran an independent laboratory that focused on the molecular biology of sarcomas, including translational opportunities and clinical trials. Dr. Matushansky received a B.A. degree, summa cum laude, from Columbia University, and a M.D. and Ph.D. in Molecular Biology from the Albert Einstein College of Medicine. He performed his internal medicine residency at New York Presbyterian Hospital/Weill Cornell Medical Center and then completed a fellowship in Medical Oncology as well as a post-doctoral research fellowship in Cancer Biology at the Memorial Sloan Kettering Cancer Center. He is currently a Clinical Assistant Professor of Medical Oncology at Columbia University. He has also been a non-executive director on the board of directors of Crescendo Biologics Ltd since June 2018.
What is the salary of Igor Matushansky?
As the Chief Medical Officer and Global Head of Research and Development of Hookipa Pharma Inc, the total compensation of Igor Matushansky at Hookipa Pharma Inc is $1,142,710. There are 2 executives at Hookipa Pharma Inc getting paid more, with Joern Aldag having the highest compensation of $6,367,980.
How old is Igor Matushansky?
Igor Matushansky is 47, he's been the Chief Medical Officer and Global Head of Research and Development of Hookipa Pharma Inc since 2017. There are 14 older and 2 younger executives at Hookipa Pharma Inc. The oldest executive at Hookipa Pharma Inc is Prof. Rolf M. Zinkernagel M.D., Ph.D., 77, who is the Co-Founder.
What's Igor Matushansky's mailing address?
Igor's mailing address filed with the SEC is C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY, 10118.
Insiders trading at Hookipa Pharma Inc
Over the last 21 years, insiders at Hookipa Pharma Inc have traded over $12,222,300 worth of Hookipa Pharma Inc stock and bought 1,455,824 units worth $18,573,557 . The most active insiders traders include Group, Llc Green Jeremy Red..., Bros. Advisors Lp Baker Bro... a Deventer Sander Van. On average, Hookipa Pharma Inc executives and independent directors trade stock every 94 days with the average trade being worth of $180,581. The most recent stock trade was executed by Reinhard Kandera on 21 August 2023, trading 7,000 units of HOOK stock currently worth $5,110.
What does Hookipa Pharma Inc do?
hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a
What does Hookipa Pharma Inc's logo look like?
Complete history of Igor Matushansky stock trades at Hookipa Pharma Inc
Hookipa Pharma Inc executives and stock owners
Hookipa Pharma Inc executives and other stock owners filed with the SEC include:
-
Joern Aldag,
Chief Executive Officer, Director -
Reinhard Kandera,
Chief Financial Officer, Director -
Igor Matushansky,
Chief Medical Officer and Global Head of Research and Development -
Joern Aldag,
CEO & Director -
Dr. Igor Matushansky M.D., Ph.D.,
Chief Medical Officer and Global Head of R&D -
Dr. Reinhard Kandera,
CFO & Director -
Sander van Deventer,
Independent Director -
Graziano Seghezzi,
Independent Director -
Jan van de Winkel,
Independent Chairman of the Board -
Michael Kelly,
Independent Director -
David Kaufman,
Independent Director -
Christoph Lengauer,
Independent Director -
Julie O Neill,
Independent Director -
Jean-Charles Soria,
Director -
Roman Necina,
Chief Technology Officer -
Klaus Orlinger,
Executive Vice President - Research -
Dr. Klaus Orlinger Ph.D.,
Exec. VP of Research -
Nina Waibel,
Sr. Director of Communications -
Marine Popoff,
Communications & Investor Relations Mang. -
Dr. Roman Necina Ph.D.,
Chief Technology Officer -
Lukas Flatz,
Co-Founder -
Andreas Bergthaler,
Co-Founder -
Prof. Rolf M. Zinkernagel M.D., Ph.D.,
Co-Founder -
Jerry D Jones,
Director -
Bros. Advisors Lp Baker Bro...,
-
Capital Fund Ii Cooperatief...,
10% owner -
David Pinschewer,
Chief Scientific Officer -
Group, Llc Green Jeremy Red...,
-
Capital Vi Fcpr Sofinnova P...,
-
Anders Lilja,
Sr. VP, Technical Development -
Timothy P. Reilly,
-
Andrew R Goeler,
Director -
Mark D Moreland,
Chief Financial Officer -
John D Jr Rogers,
Director -
Martin J Iv Wall,
Vice President, Sales -
David R Lord,
Director -
V Sebastian Pastore,
VP, Brewing Operations & Tech -
Marc J Cramer,
Director -
Terry E Michaelson,
Co-Chief Executive Officer -
Kurt R Widmer,
Director -
Danielle A Katcher,
Vice President, Marketing -
Kevin R Kelly,
Director -
Timothy P Boyle,
Director -
David J Mickelson,
President & COO -
Companies, Inc.Busch Invest...,
-
Frank H Clement,
Director -
Ann G Widmer,
10% owner -
Anthony J Short,
Director -
Kurt R Widmer Ann G Widmer,
-
Paul S Shipman,
President & CEO -
Michael Loughran,
Director -
Katia Schlienger,
Chief Medical Officer -
Jorn Aldag,
Chief Executive Officer -
Christine D. Baker,
Chief Operating Officer -
Mark Winderlich,
Chief Development Officer -
Mary Theresa Coelho,
EVP and CFO -
Malte Peters,
Chief Executive Officer -
Sean A Cassidy,